MX368228B - Anticuerpos que se unen específicamente a her2. - Google Patents
Anticuerpos que se unen específicamente a her2.Info
- Publication number
- MX368228B MX368228B MX2015015110A MX2015015110A MX368228B MX 368228 B MX368228 B MX 368228B MX 2015015110 A MX2015015110 A MX 2015015110A MX 2015015110 A MX2015015110 A MX 2015015110A MX 368228 B MX368228 B MX 368228B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- her2
- present
- cancer
- trastuzumab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un anticuerpo HER2 novedoso para su administración simultánea, que se utiliza para prevenir o tratar cáncer. El anticuerpo de la presente invención se une específicamente a HER2, el cual se sobre-expresa en células de cáncer (particularmente, en células de cáncer de mama y cáncer gástrico), y se une a un epítopo diferente de aquel al cual se une trastuzumab. El anticuerpo de la presente invención tiene una secuencia única debido a una homología muy baja comparada con la secuencia CDR de los anticuerpos dirigidos a HER2 conocidos. El anticuerpo de la presente invención extermina células de cáncer con una capacidad notablemente mejorada para exterminar células de cáncer cuando se administra simultáneamente con trastuzumab y de este modo, es muy útil para prevenir o tratar cáncer (particularmente cáncer de mama o cáncer gástrico). La eficacia notable de la administración simultánea del anticuerpo de la presente invención se considera, sin desear limitarse por la teoría que se debe a que el anticuerpo de la presente invención se une a un epítopo de HER2 diferente al que se une trastuzumab, inhibiendo por lo tanto HER2 de forma cooperativa con trastuzumab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130055912 | 2013-05-16 | ||
PCT/KR2014/004317 WO2014185704A1 (ko) | 2013-05-16 | 2014-05-14 | Her2에 특이적으로 결합하는 항체 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015015110A MX2015015110A (es) | 2016-08-11 |
MX368228B true MX368228B (es) | 2019-09-24 |
Family
ID=51898619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015015110A MX368228B (es) | 2013-05-16 | 2014-05-14 | Anticuerpos que se unen específicamente a her2. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10174116B2 (es) |
EP (1) | EP2998319B1 (es) |
JP (2) | JP6234548B2 (es) |
KR (1) | KR101453462B1 (es) |
CN (1) | CN105164160B (es) |
AU (1) | AU2014266118B2 (es) |
BR (1) | BR112015027400B1 (es) |
CA (1) | CA2910407C (es) |
ES (1) | ES2710707T3 (es) |
HK (1) | HK1217500A1 (es) |
MX (1) | MX368228B (es) |
RU (1) | RU2628094C2 (es) |
WO (1) | WO2014185704A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101884585B1 (ko) * | 2010-02-10 | 2018-08-01 | 우베 고산 가부시키가이샤 | 폴리이미드 필름, 이를 포함하는 폴리이미드 적층체, 및 이를 포함하는 폴리이미드/금속 적층체 |
TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
KR101796277B1 (ko) * | 2016-04-12 | 2017-11-13 | 앱클론(주) | 안정성이 개선된 her2에 특이적으로 결합하는 항체 |
EP3241847A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Her-2 binding antibodies |
CN109476744B (zh) * | 2016-05-12 | 2023-04-11 | 新加坡科技研究局 | 抗erbb-2抗体及其用途 |
US11390685B2 (en) | 2017-01-06 | 2022-07-19 | Biosion, Inc. | ErbB2 antibodies and uses therefore |
BR112019017628A2 (pt) * | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
JP7386796B2 (ja) * | 2017-11-14 | 2023-11-27 | グリーン クロス ラボ セル コーポレーション | 抗-her2抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体 |
CN110790840A (zh) * | 2018-08-01 | 2020-02-14 | 三生国健药业(上海)股份有限公司 | 结合人her2的抗体、其制备方法和用途 |
KR20200098831A (ko) | 2019-02-13 | 2020-08-21 | 건국대학교 글로컬산학협력단 | 신규한 부위-특이적 항체 절편 플랫폼 |
EP3962525A1 (en) * | 2019-05-02 | 2022-03-09 | MAB Discovery GmbH | Combination of her2 antibodies |
CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
EP0349578B2 (en) | 1987-03-02 | 1998-10-28 | Enzon Labs Inc. | Organism carrying a Single Chain Antibody Domain at its surface. |
DE3884529T2 (de) | 1987-03-20 | 1994-04-28 | Creative Biomolecules Inc | Leader-anteile zur produktion von rekombinanten proteinen. |
ATE113985T1 (de) | 1987-03-20 | 1994-11-15 | Creative Biomolecules Inc | Verfahren zur reinigung von rekombinanten polypeptiden. |
EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
CA2120745A1 (en) | 1992-06-30 | 1994-01-06 | Philip G. Kasprzyk | A combination of anti-erbb-2 monoclonal antibodies and method of using |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
CN101412758A (zh) * | 1996-10-18 | 2009-04-22 | 基因技术股份有限公司 | 抗ErbB2抗体 |
US7306801B2 (en) * | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
WO2005044302A1 (en) | 2003-11-06 | 2005-05-19 | Pfizer Products Inc. | Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
CN103127502A (zh) | 2004-05-20 | 2013-06-05 | 津莫吉尼蒂克斯公司 | 使用il-21和单克隆抗体疗法治疗癌症的方法 |
KR20070038557A (ko) * | 2004-07-22 | 2007-04-10 | 제넨테크, 인크. | Her2 항체 조성물 |
JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | hK1結合タンパク質 |
JP5638804B2 (ja) * | 2006-08-04 | 2014-12-10 | アストラゼネカ アクチボラグ | ErbB2に対する抗体 |
WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
US9155753B2 (en) | 2007-03-09 | 2015-10-13 | Geron Corporation | Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors |
WO2011001276A1 (en) | 2009-06-30 | 2011-01-06 | Philogen S.P.A. | Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer |
CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
CA2832387A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
-
2014
- 2014-05-13 KR KR1020140057321A patent/KR101453462B1/ko active IP Right Grant
- 2014-05-14 WO PCT/KR2014/004317 patent/WO2014185704A1/ko active Application Filing
- 2014-05-14 RU RU2015146664A patent/RU2628094C2/ru active
- 2014-05-14 CN CN201480024152.3A patent/CN105164160B/zh active Active
- 2014-05-14 EP EP14798440.5A patent/EP2998319B1/en active Active
- 2014-05-14 AU AU2014266118A patent/AU2014266118B2/en active Active
- 2014-05-14 ES ES14798440T patent/ES2710707T3/es active Active
- 2014-05-14 CA CA2910407A patent/CA2910407C/en active Active
- 2014-05-14 JP JP2016508909A patent/JP6234548B2/ja active Active
- 2014-05-14 BR BR112015027400-5A patent/BR112015027400B1/pt active IP Right Grant
- 2014-05-14 MX MX2015015110A patent/MX368228B/es active IP Right Grant
- 2014-05-14 US US14/781,968 patent/US10174116B2/en active Active
-
2016
- 2016-05-12 HK HK16105433.6A patent/HK1217500A1/zh unknown
-
2017
- 2017-07-06 JP JP2017132833A patent/JP6487968B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2998319A4 (en) | 2017-01-25 |
CA2910407A1 (en) | 2014-11-20 |
BR112015027400A2 (pt) | 2017-08-29 |
CN105164160B (zh) | 2018-11-30 |
RU2628094C2 (ru) | 2017-08-14 |
CN105164160A (zh) | 2015-12-16 |
US10174116B2 (en) | 2019-01-08 |
WO2014185704A1 (ko) | 2014-11-20 |
EP2998319B1 (en) | 2018-11-28 |
RU2015146664A (ru) | 2017-06-21 |
AU2014266118B2 (en) | 2017-03-30 |
ES2710707T3 (es) | 2019-04-26 |
JP6234548B2 (ja) | 2017-11-22 |
AU2014266118A1 (en) | 2015-11-12 |
BR112015027400B1 (pt) | 2023-04-25 |
JP2016518368A (ja) | 2016-06-23 |
KR101453462B1 (ko) | 2014-10-23 |
US20160053011A1 (en) | 2016-02-25 |
JP6487968B2 (ja) | 2019-03-20 |
EP2998319A1 (en) | 2016-03-23 |
HK1217500A1 (zh) | 2017-01-13 |
MX2015015110A (es) | 2016-08-11 |
CA2910407C (en) | 2018-12-11 |
JP2018008954A (ja) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015015110A (es) | Anticuerpos que se unen especificamente a her2. | |
SA522431756B1 (ar) | Tigit أجسام مضادة لـ | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
MX2014001374A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
MX2016012124A (es) | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. | |
PH12016501672A1 (en) | Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia | |
MX348579B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2017016253A (es) | Anticuerpos para cd40. | |
WO2019014328A3 (en) | AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | |
MY184628A (en) | Afucosylated anti-fgfr2iiib antibodies | |
TN2015000396A1 (en) | Antibody drug conjugates | |
MX2016005666A (es) | Anticuerpos anti-cd38 especificos para tratar canceres humanos. | |
JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
NZ630864A (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
MX2018014560A (es) | Metodos para el tratamiento de la miastenia gravis generalizada refractaria. | |
MX2020002406A (es) | Anticuerpo anti-epha4. | |
SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
NZ625758A (en) | Method for treating breast cancer | |
EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
WO2019100052A3 (en) | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof | |
PH12016500677A1 (en) | Specific anti-cd38 antibodies for treating human cancers | |
MX2013002718A (es) | Composiciones de anticuerpo anti-vegfr-3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |